The agreement adds a new product to Venus Concept's portfolio but lacks disclosed financial terms, making near-term revenue impact speculative. Monitor for initial order volumes or revenue guidance in future filings to gauge adoption. The stock's OTC listing and low analyst bullishness (0% strong buy) suggest limited institutional interest; any positive read-through from this deal is likely modest.
Price Chart
Executive Summary
Venus Concept entered an exclusive distribution agreement with HIRONIC Co. Ltd. to distribute the Doublo 2.0 device in the U.S. and Canada. The device, which has FDA 510(k) clearance, combines Cold Plasma and RF microneedling and is expected to launch in 2H 2026. This is a product-line expansion for Venus Concept but does not include financial terms, so the immediate revenue impact is unquantifiable.
Key Facts
- Exclusive distribution agreement with HIRONIC for Doublo 2.0 device in U.S. and Canada.
- Device has FDA 510(k) certification; U.S. launch expected in 2H 2026.
- Device combines Cold Plasma and RF microneedling technologies.
- No financial terms (upfront payments, minimum guarantees, or revenue sharing) disclosed.
- Venus Concept will support future Canadian regulatory approval for the device.
Financial Impact
No financial terms disclosed; revenue contribution depends on adoption and pricing, which are not stated.
Risk Factors
- No financial terms disclosed — deal economics (upfront fees, minimums, margins) are unknown.
- Device launch in 2H 2026 may be delayed by regulatory or manufacturing issues.
- Venus Concept's OTC listing and weak analyst consensus (0% bullish) indicate ongoing business challenges that may limit the deal's impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334139 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Apr 1, 2026 29w ago | Press Release | $0.3010 | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers